Non-squamous Non-small-cell Lung Cancer
Conditions
Interventions
Patients receive paclitaxelon days 1,8,15 and Carboplatin(AUC6) on day1 and Bevacizumab (15mg/kg) on day1, every four weeks, up to six cycles. Patients who still control disease without unacceptable
Sponsors
Hiroshima Asa City Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically determined non small cell lung cancer 2) Unresectable or StageIIIB or IV without any indications for radiotherapy 3) Have measurable lesions by RECIST 4) No prior chemotherapy 5) Aged 20 to 74 years old 6) ECOG perfornmance status 0 or 1 7)8) adequate organ function 9)Patients are excepted to live at least 3 months 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Squamous cell lung cancer 2) History of Severe drug allergies. 3) Double malignancies within 5 years 4) Uncontrolled ascites, pleural effusion or cardiac effusion 5) Current history of hemoptysis 6-7) High risk of bleeding or thrombus events 8) Evidence of bleeding diathesis or coagulopathy 9) Current or previous history of Pericardial effusion 10) Superior vena cava syndrome 11) Spinal cord compression 12) Current or previous (within the last 1 year) history of cerebrovascular disease 13) Traumatic fracture of unrecovery 14) History of active infection 15) Scheduled operation 16) Antithrombotic agent 17) Uncontrollable Gastrointestinal ulceration 18) Current or previous (within the last 1 year)history of GI perforation 19) Uncontrollable hypertension 20) Severe cardiac disease 21) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 22) With grade2 or more neuropathy 23) Treatment history of bevacizumab 24) Pregnancy, breastfeeding or suspected of being pregnant 25) HBs positive patient 26) Others judged by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PhaseI Recommended Dose PhaseII Response Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| DCR, PFS, OS, Safety | — |
Countries
Japan
Contacts
Public ContactSouichi Kitaguchi
Hiroshima Asa City Hospital Medical oncology/Respiratory medicine
Outcome results
None listed